Anisperimus
Alternative Names: LF 15-0195Latest Information Update: 10 Oct 2003
At a glance
- Originator Groupe Fournier
- Class
- Mechanism of Action Immunosuppressants; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 10 Oct 2003 Discontinued - Phase-I for Transplant rejection in France (IV)
- 10 Oct 2003 Discontinued - Phase-I for Transplant rejection in France (SC)
- 10 Oct 2003 Discontinued - Phase-II for Autoimmune disorders in Europe (IV)